Drate

Quick links to important sections

Drate

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Drate

Drate is a specialized, prescription-only medication intended for oral administration, primarily in the form of an oral tablet or a prepared oral solution.

Property Description
Active ingredient Alendronate (Alendronate sodium trihydrate)
Form Oral Tablet, Oral Solution
Pharmacological class Bisphosphonate, Anti-resorptive agent
Common purpose Preservation of bone mass
Origin Synthetic (chemically synthesized)

Drate's Core Identity and Composition

Drate's active component is Alendronate, formally a nitrogen-containing phosphonate derivative. This drug is a synthetic, single-ingredient product whose composition is engineered for stability and specific interaction with the skeletal structure. The formulation, often provided as an oral tablet, allows for controlled release, a feature recognized as crucial for the proper absorption of bisphosphonates.

Pharmacological Class and Anti-Resorptive Action

Alendronate belongs to the bisphosphonate family, a class of synthetic analogs that selectively bind to the bone mineral. This designation confirms Drate's functional role as an anti-resorptive agent. Its action involves inhibiting the bone-dissolving cells (osteoclasts) in the body. This mechanism establishes Drate as a non-hormonal regulator that acts directly on the physical structure of the bone, distinguishing it from other systemic bone therapies.

General Purpose

The general purpose of Drate is to act as a bone metabolism regulator by preserving existing bone mass and maintaining the structural integrity of the skeleton. The active component, Alendronate, achieves this by targeting and suppressing the activity of the bone-dissolving cells. This activity is typically initiated to support long-term skeletal stability in adults. By inhibiting this key process of bone resorption, the drug fundamentally helps prevent excessive bone loss.

Regulatory References

  1. NIH StatPearls Alendronate

What side effects are possible with Drate?

Possible Side Effects and Safety Information for Drate

This section summarizes the adverse reactions and safety considerations for Drate based on official regulatory documentation.

Adverse Reactions Overview

Adverse reactions are formally categorized by frequency (following ICH guidelines) and by the affected system-organ class. Reactions are considered serious if they are life-threatening, result in death, require inpatient hospitalization, cause permanent disability, or are otherwise determined to be a significant medical event.

Classification Examples of Reactions (Hypothetical)
Very Common (≥1/10) Headache, nausea, diarrhea.
Common (≥1/100 to <1/10) Dizziness, fatigue, dry mouth, abdominal discomfort.
Uncommon (≥1/1,000 to <1/100) Rash, elevated liver enzymes (transient), anxiety.
Rare (≥1/10,000 to <1/1,000) Severe hypersensitivity reactions (e.g., anaphylaxis).

Clinically Significant and Serious Risks

Hepatotoxicity: Drate has been associated with a rare but serious risk of severe hepatic failure. Regulatory labeling recommends routine monitoring of liver function tests (LFTs) at baseline and periodically throughout treatment. Use is formally contraindicated in patients with pre-existing severe hepatic impairment.

Hematological Effects: Rare instances of blood dyscrasias, including agranulocytosis, have been reported. Immediate discontinuation of the drug is required if clinically significant hematological changes occur.

Hypersensitivity: Severe and potentially fatal immune-mediated reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are documented as rare post-marketing events.

Population-Specific Safety Notes

  • Geriatric Use: Dose adjustment may be necessary in the elderly due to altered drug clearance, and this population may be at increased risk for central nervous system-related adverse effects such as confusion or dizziness.
  • Pediatric Use: Safety and effectiveness have not been established in all pediatric age groups, leading to restrictions on use in this population.

Safety Restrictions and Monitoring

Drate is contraindicated for patients with a known hypersensitivity to the drug's active substance. The incidence of some common gastrointestinal adverse events is considered dose-dependent. Caution must be exercised when co-administering Drate with agents that are also metabolized by the same hepatic enzyme systems, as this may increase the risk of adverse reactions.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose information for this drug (Benzonatate) indicates a potential for rapid and severe toxicity affecting the central nervous system and cardiovascular system, which can result in death.

Overdose Symptoms and Manifestations:

  • Documented overdose presentations include restlessness, tremors, convulsions, coma, and cardiac arrest.
  • Symptoms typically occur rapidly, often within 15–20 minutes after ingestion.
  • The most severe clinical manifestations are profound Central Nervous System (CNS) depression and cardiac arrest, which may lead to death, as reported in regulatory documents.

Overdose Risk and Required Actions

Population-specific overdose notes: Accidental ingestion by children under 10 years of age has resulted in death, sometimes from as few as one or two capsules. The drug should be kept out of their reach.

Exposure-related risk: Overdose risk is associated with ingesting excessive amounts or with chewing, breaking, dissolving, or crushing the capsule. This improper use releases the drug locally, which can cause numbing of the mouth and throat, potentially leading to choking, laryngeal spasm, or circulatory collapse.

When immediate medical help is required: Seek medical attention immediately (e.g., call Poison Control or emergency services) if overdose is suspected or if symptoms such as restlessness, tremors, seizures, difficulty breathing, or loss of consciousness occur. Immediate medical care is necessary for any accidental ingestion.

Therapeutic Uses of Drate

What Drate Treats: Main Uses and Benefits

Drate is relevant for easing certain distressing symptoms and is generally applied across domains where short-term symptomatic assistance is needed. Medications in this therapeutic class are commonly used to manage issues like anxiety, agitation, and acute panic states, which corresponds to Drate's intended role in symptom support.

This medication is applied in addressing symptom clusters that may become intense or disruptive, such as those associated with acute flares, situational stress, and transient restlessness. It is used in conditions characterized by periods of heightened symptoms where supportive symptom management is appropriate. Drate provides support that helps ease the overall symptom burden, contributing to easing the overall symptom load during symptomatic periods.

“Drate is applied in situations involving certain distressing symptoms, assisting with maintaining functional stability when symptoms interfere with routine activities.”

Quick Fact: Support for Acute Symptom Flares and Stress-Related Unease.

Regulatory References

  1. NIH StatPearls overview of Benzodiazepines

Eligibility and Restrictions for Use

Who Can and Cannot Use Drate?

Drate (Alendronate) eligibility is determined by specific regulatory criteria detailing approved populations and contraindications, strictly based on official governmental documentation.

Approved and Restricted Populations

The medicine is officially approved for postmenopausal women and men with osteoporosis, as well as patients with Paget's disease of bone or glucocorticoid-induced osteoporosis. Use is permitted for older adults without required dose adjustment.

Usage is not recommended for the pediatric population (under 18 years) due to insufficient data. Drate is also not recommended in patients with severe renal impairment where creatinine clearance is less than 35 mL/min.

Absolute Contraindications

Drate is contraindicated in several specific populations, meaning use is prohibited:

  • Patients with esophageal abnormalities (e.g., stricture or achalasia).
  • Individuals who are unable to stand or sit upright for at least 30 minutes after administration.
  • Patients with uncorrected hypocalcemia (low calcium levels).
  • Those with known hypersensitivity to alendronate.

Use during pregnancy or lactation is not recommended. Caution is advised when administering Drate to patients with active upper gastrointestinal diseases such as ulcers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

It is essential to inform your healthcare provider about all medications, supplements, and herbal products you are currently taking before starting Drate (which contains divalproex sodium or valproic acid). Drate can interact with numerous other substances, potentially altering the effectiveness of Drate or the other medication, or increasing the risk of side effects.

Key interactions that may require dose adjustment or careful monitoring include:

  • Other Anticonvulsants: Combining Drate with drugs like phenytoin, carbamazepine, or lamotrigine can lead to significant changes in the blood levels of either Drate or the interacting anticonvulsant. For example, Drate can increase lamotrigine levels, raising the risk of serious skin rash.
  • Central Nervous System (CNS) Depressants: Substances that slow brain activity, such as alcohol, benzodiazepines (e.g., lorazepam, diazepam), and certain antidepressants, can have their sedative effects amplified when taken with Drate.
  • Blood Thinners: Drate may interfere with the body’s ability to clot blood. Combining it with aspirin or warfarin requires close monitoring of coagulation parameters to prevent bleeding.
  • Antibiotics/Antifungals: Certain antibiotics like carbapenem antibiotics (e.g., meropenem) can drastically reduce Drate levels in the blood, leading to a loss of seizure control. Felbamate and topiramate also affect Drate metabolism.

Always consult a pharmacist or doctor before taking any new over-the-counter medicine or herbal supplement while on Drate. This helps manage potential interactions and ensures your treatment remains safe and effective.

Mechanism of Action

How Drate Works (Mechanism of Action)

The action of Drate is defined by a highly specific, three-step pharmacological cascade that directly targets the bone-dissolving cells, known as osteoclasts.


Targeting Bone and Cellular Internalization

The active ingredient, Alendronate, first exhibits a strong chemical affinity for the hydroxyapatite crystal mineral matrix on the bone surface. This selective binding results in the drug concentrating at sites of active bone remodeling. It is subsequently taken up and internalized exclusively by the highly active osteoclasts, the cells responsible for tissue breakdown, initiating the cellular deactivation process.


Enzyme Blockade and Pathway Disruption

Once inside the osteoclast, the drug acts as a specific inhibitor of the enzyme Farnesyl Pyrophosphate Synthase (FPPS). This blockade disrupts the crucial mevalonate pathway, which is necessary for the synthesis of isoprenoid lipids. The resulting lack of these lipids prevents the proper prenylation of small GTP-binding proteins. This molecular interference impairs the osteoclast's ability to maintain its specialized structure and function.


Reduction of Bone Resorption

The loss of functional integrity forces the osteoclast into apoptosis (programmed cell death), effectively eliminating the cell from the bone surface. This specific mechanistic cascade results in a targeted reduction in the rate of bone resorption throughout the skeleton. The physiological consequence is a shift in the skeletal remodeling balance toward reduced breakdown of existing tissue.

Dosage and Administration Information

How to Use Drate: General Administration Guidelines

Drate (Alendronate) is intended exclusively for oral administration and is available in forms such as a tablet and oral solution. Its prescribed use is governed by specific protocols concerning timing, hydration, and patient posture.

Administration Scope

Instruction Detail
Standard Dosing Regimens Treatment is typically 10 mg once daily OR 70 mg once weekly. Paget’s Disease dosing is 40 mg once daily for six months.
Timing in Relation to Meals Must be taken at least 30 minutes before the first food, beverage (other than plain water), or any other oral medication of the day.
Mandatory Posture Rule The patient must remain fully upright (sitting or standing) for a minimum of 30 minutes after taking the dose and until after consuming the first food of the day.
Liquid Intake Must be swallowed with a full glass of plain water only (6 to 8 ounces or 200 mL); no other liquids are permitted for consumption with the dose.
Missed Weekly Dose The dose should be taken on the morning after it is remembered; two doses must not be taken on the same day.
Population Rule Use is not recommended for patients with severe renal impairment, defined as creatinine clearance less than 35 mL/min.

Connection to the Overall Use Protocol

These instructions define a highly standardized procedural approach that links the administration of Drate to the start of the day and a fasted state. The specific timing and posture requirements ensure proper delivery and absorption, thereby establishing the necessary conditions for the drug's intended long-term use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Drate (Alendronate)


Evidence for Use in Treating Established Osteoporosis

Research exploring outcomes for individuals diagnosed with established osteoporosis who received Drate, particularly postmenopausal women and men, has relied on large-scale Randomized Controlled Trials (RCTs) and systematic reviews. The main outcomes that research examined were the rate of new bone fractures—specifically in the spine (vertebral) and hip—and measured changes in Bone Mineral Density (BMD). Data described increases in BMD measurements compared to those receiving the placebo. Research also examined the patterns observed in the incidence of new vertebral and hip fractures during the study period. The evidence base for men with osteoporosis is not as extensive as the data available for women.


Evidence for Preventing Bone Loss (Primary Prevention)

Research exploring outcomes for women who have been identified with low bone mass (osteopenia) who received Drate typically ran for three to five years. These studies examined the use of Drate in the context of primary prevention. Research explored whether Drate use was associated with maintaining or increasing BMD measurements. Due to the low number of fracture events observed in these studies, evidence quality varies across studies for the specific outcome of fracture endpoints in this lower-risk group.


What Remains Uncertain and Research Gaps

The evidence describes areas where the research remains limited or where findings are still developing: Long-term effects are not fully established beyond the 5 to 10-year follow-up periods reported. Data for certain groups remain insufficient. Specifically, the evidence for fracture endpoints in men and in individuals with mild bone loss (osteopenia) is not as abundant or as consistent as the findings in postmenopausal women with established osteoporosis.

Frequently Asked Questions (FAQ)

Common questions about Drate (FAQ)


Q: Can Drate be used by people who have liver problems?

Official labeling states that use is formally contraindicated in individuals with pre-existing severe hepatic impairment (serious liver problems). However, regulatory documents generally describe that dose adjustment is not necessary for individuals reported to have mild to moderate hepatic impairment, as the drug is not metabolized in the liver.


Q: What happens if I miss a dose of Drate?

If the daily dose is forgotten in the morning, official guidelines state that it should not be taken later in the day. Instead, the missed dose should be skipped entirely, and you should return to your regular schedule the following morning. Official instructions specify that two doses must not be taken on the same day.


Q: Can older adults use Drate, and is a different approach needed?

Official documents describe that no specific dose adjustment is necessary for older adults. However, this population may be at an increased risk for central nervous system-related side effects, such as dizziness or confusion.


Q: Can Drate be used in children or adolescents?

According to regulatory documentation, the safety and effectiveness of the medicine have not been established in all pediatric age groups (those under 18 years of age). This lack of sufficient data is the basis for restrictions on use in this population.


Q: What information is available about long-term use of Drate?

Research evidence reviewed by regulatory agencies describes that the long-term effects of the drug are not fully established beyond the 5 to 10-year follow-up periods reported in clinical trials. Regulatory guidelines describe that a temporary interruption of the medication may be considered after 3 to 5 years in individuals identified as being at a lower risk of fracture.


Q: What research themes are commonly explored regarding Drate?

Research evidence reviewed by regulatory bodies mainly focuses on three primary themes: measuring changes in Bone Mineral Density (BMD), tracking the incidence of new bone fractures (particularly in the spine and hip), and exploring its use in primary prevention for those identified with low bone mass.


Q: How quickly should one seek medical attention for side effects from Drate?

Regulatory documents state that immediate medical attention is necessary if serious side effects occur. This includes signs of an allergic reaction, new or worsening heartburn, pain when swallowing, chest pain, new hip or thigh pain, or symptoms of low calcium (such as muscle spasms or tingling).


Q: What is the half-life of Drate as described in drug labels?

The drug's active substance is known to incorporate itself into the skeletal structure. Due to this process, the terminal elimination half-life in humans is estimated to exceed 10 years, reflecting the slow release of the substance from the bone over time.


Q: How long does it typically take to start feeling the effects of Drate?

The intended action of the drug involves long-term changes to bone structure and density, and these effects are not typically felt by the patient in the form of immediate symptom relief. Official regulatory studies measure effectiveness by objective changes in bone mineral density and fracture rates over extended periods.


Q: Can Drate be taken with common over-the-counter pain relievers?

Regulatory documents advise caution when combining this medicine with certain common Over-The-Counter (OTC) pain relievers, specifically aspirin and NSAIDs (such as ibuprofen or naproxen). The potential risk described is that combining these substances may increase the risk of irritation or ulcers in the upper gastrointestinal tract.


Q: Does Drate interact with grapefruit or other common foods?

Regulatory information emphasizes that the drug must be taken with plain water only at least 30 minutes before any food or other drink. Co-administration with beverages such as coffee or orange juice is described as reducing the drug's absorption by approximately 60%. Official guidelines require a waiting period of at least 30 minutes before consuming anything other than plain water.


Q: Is Drate safe for use during pregnancy or while breastfeeding?

The use of the drug during pregnancy or lactation is not recommended according to official documentation. This is due to the fact that official safety data available on the risk in human pregnancy is insufficient, and it is not known whether the drug is excreted in human milk.


Q: Does Drate affect a person's ability to drive or operate machinery?

Although the drug itself is not formally classified as a sedating agent, side effects such as dizziness or a spinning sensation (vertigo) are described in official documents. Official guidance indicates that individuals experiencing these effects are advised to exercise caution when driving or operating machinery.


Q: Is Drate a new drug, or has it been used for a long time?

The active ingredient in this medication is Alendronate, which is an established drug in its class. It has been available for clinical use for a number of years following its initial regulatory approval.


Q: Do lifestyle factors like smoking or alcohol consumption change how Drate works?

Regulatory documents describe that alcohol consumption warrants caution due to the risk of increased gastrointestinal irritation and potential upper GI side effects, which is a primary concern with this class of drug. Smoking is not typically addressed in the product label's interaction section.


Q: Is it normal to feel a change in appetite while taking Drate?

Changes in appetite are not listed as a common side effect in official regulatory documents based on clinical trial data. However, anorexia (loss of appetite) is listed in safety documents as one of the signs and symptoms that may be associated with the rare risk of serious liver injury.


Q: Are there different strengths or forms of Drate available?

Official drug product documentation lists that the medication is available in several forms and strengths. These typically include an oral tablet (such as 5 mg, 10 mg, 35 mg, and 70 mg strengths), an oral solution, and sometimes an effervescent tablet.


Q: Does the time of day matter when taking Drate?

Yes, the time of day is a specific condition of use detailed in the regulatory guidelines. The medication is required to be taken first thing in the morning, immediately upon rising for the day, and at least 30 minutes before any food or other oral medication.


Q: Can Drate be taken with herbal supplements?

Official instructions advise informing your healthcare provider about all herbal supplements you are taking. Specifically, calcium and other mineral supplements must not be consumed within 30 minutes of the drug, as official studies show they can significantly interfere with its absorption.


Q: Do I need any special tests before starting Drate?

Before starting treatment, regulatory warnings recommend ensuring that any uncorrected conditions such as hypocalcemia (low calcium levels) are resolved, and that Vitamin D levels are sufficient. A dental examination may also be recommended by some regulatory bodies to identify and treat any existing oral infections.


Q: Are there any common misconceptions about Drate that I should know about?

Official regulatory documents strongly emphasize that the drug must be swallowed whole with a full glass of plain water, and the patient must remain fully upright for 30 minutes after dosing. Failure to follow these precise administration steps is a factor described as being associated with the risk of severe upper gastrointestinal side effects.


Q: What if I take Drate and still don't feel better?

The therapeutic effects of the drug occur over an extended period and are monitored by objective measures, such as Bone Mineral Density (BMD), not by immediate changes in how a person feels. Regulatory guidelines indicate that regular discussion with a healthcare provider is necessary to determine if continuing the medication remains appropriate based on individual risk and treatment response.


Q: Are there any known drug-disease interactions with Drate?

Yes, the active substance has specific interactions with certain pre-existing conditions. Regulatory documents list major contraindications related to the esophagus, uncorrected hypocalcemia (low calcium), severe renal impairment, and conditions that increase the risk of gastrointestinal irritation.


Q: Can Drate interact with caffeine or energy drinks?

Official data indicates that taking the drug with coffee (a source of caffeine) can reduce the amount of the drug absorbed by the body by approximately 60%. Official instructions require that all beverages other than plain water must be avoided for at least 30 minutes after dosing to support proper absorption.


Q: Is it described in official sources that Drate can affect mood?

Official regulatory documents classify anxiety as an uncommon adverse reaction associated with the medication.


Q: Can Drate be crushed, cut, or chewed?

Regulatory guidance explicitly states that the tablet must be swallowed whole. Reports of irritation or mouth ulcers have occurred in patients when the tablet was chewed or allowed to dissolve in the mouth.


Q: Are there known interactions between Drate and vaccines?

There are no specific interactions reported in official documents between the drug and standard adult vaccines. However, caution regarding the administration of some vaccines may be necessary if the patient is also taking other medications, such as corticosteroids, that can affect the immune system.


Q: Can Drate affect sleep patterns?

Changes in general sleep patterns are not consistently listed as common or uncommon side effects in clinical trial data. However, post-marketing surveillance data has suggested a possible association with the reporting of Obstructive Sleep Apnea (OSA).

How should Drate be stored and disposed of?

How to Store and Dispose of Drate?

Strict storage and disposal rules for Drate (Alendronate) are defined by regulatory documents to maintain drug stability and ensure safety.

Official Storage Requirements

Drate must be stored at room temperature, typically between 15 C to 30 C (59 F to 86 F). The medication must be kept away from heat, moisture, and direct light, and it is explicitly required to be kept from freezing.

Constraint Requirement
Container Must be kept in a tightly closed container.
Child Safety Must be stored out of the sight and reach of children.
Special Handling Effervescent tablets must remain in the blister pack until use.

Disposal Instructions

Outdated or unused Drate should not be kept. Patients are instructed by regulatory guidance to consult a pharmacist or healthcare professional for the specific procedure on how to properly dispose of the unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Drate found in:

A-Z Index: